Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New data show that AI could enhance imaging-based screening for pancreatic cancer; however, its evaluation must be rigorous and adhere to the same standards used for conventional screening.
In a phase 2 trial, the oral type II RAF inhibitor tovorafenib exhibited an overall response rate of 67% in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma.
A citizen science approach has helped craft a resource-rich vaginal microbiome map with associations to lifestyle and events across a woman’s life course.
A year ago, we adopted an ethics framework to help with the assessment of and to increase transparency and accountability for research practices in studies involving partnerships between researchers in high- and low-income settings. We now reflect on our progress, what we learned and the way forward to champion ethical, inclusive and equitable partnerships in the content we publish.
Analysis of hematopoietic stem cells from six individuals with sickle cell disease who had been treated with autologous gene therapy revealed positive selective pressure on cells containing mutations in genes associated with clonal hematopoiesis and hematological malignancies.
Wireless sensing devices placed on the skin can capture a wide spectrum of acoustic and mechanical signals at several body locations simultaneously for monitoring of internal body processes such as cardiorespiratory function, gastrointestinal activity, swallowing and respiration.
In a phased prospective rollout, the implementation of AI as an additional reader for mammography screening improved the real-world early detection of breast cancer compared to standard double reading involving two independent radiologists.
We asked the winners of the Nature Award for Inclusive Health Research to share their key lessons for conducting medical research in partnership with under-represented communities.
A quadrivalent vaccine against human papillomavirus produced by the Serum Institute of India was shown to be noninferior to the established quadrivalent vaccine — boosting global efforts to eliminate cervical cancer.
A phase 1 trial of an IRAK4-targeted protein degrader in patients with chronic inflammatory skin diseases hits an important milestone for the safe application of this drug class beyond oncology.
The induction of neutralizing antibodies is the main goal of an HIV-1 vaccine, although data on the longevity of such antibodies is lacking. By tracking neutralizing antibodies in a large cohort of individuals infected with HIV-1 who had varying viral loads, we show that the HIV-1 neutralization response can last for several years even at low antigen levels.
Two modelling studies offer compelling evidence that less-than-perfect adherence to HIV pre-exposure prophylaxis can still provide reasonable protection for cisgender women — providing optimism for a more person-centered approach and lower discontinuation rates.
In a post hoc analysis of the phase 2 PRADO trial, baseline emotional distress was associated with reduced clinical responses in patients with stage III melanoma treated with neoadjuvant ipilimumab and nivolumab.
Distinct signatures of the airway microbiota associate with acute respiratory distress syndrome, hospital-acquired pneumonia and prolonged mechanical ventilation, and may help to inform clinical outcomes in critically ill patients.
Modeling shows that antiretroviral treatment as pre-exposure prophylaxis (PrEP) can be highly effective in cisgender women at preventing HIV-1 acquisition, but underscores the need to understand the barriers that limit PrEP adherence in women.